    5 WARNINGS AND PRECAUTIONS



  EXCERPT:   Infusion reactions may occur. Premedicate with diphenhydramine. Slow or interrupt infusion and administer treatment based on severity of the reaction. (  5.1  )



 



   5.1 Infusion Reactions



   Infusion≠B-OSE_Labeled_AE  -≠I-OSE_Labeled_AE  related≠I-OSE_Labeled_AE   reactions≠I-OSE_Labeled_AE  were reported during administration of raxibacumab in clinical trials including reports of  rash≠B-OSE_Labeled_AE ,  urticaria≠B-OSE_Labeled_AE , and  pruritus≠B-OSE_Labeled_AE . If these reactions occur, slow or interrupt raxibacumab infusion and administer appropriate treatment based on severity of the reaction.



 Premedicate with diphenhydramine within 1 hour prior to administering raxibacumab to reduce the risk of  infusion≠B-NonOSE_AE   reactions≠I-NonOSE_AE  [see Dosage and Administration (  2.1  ), Adverse Reactions (  6.1  )].  
